Last updated: April 24, 2026
China Patent CN1946353: Scope, Claims, and Landscape
CN1946353 is a Chinese patent publication tied to a defined chemical/medicinal invention. It sits inside a dense field of related compounds, with claim scope that typically tracks (1) the defined chemical structure class and (2) method-of-preparation and/or use categories that follow Chinese practice for pharmaceutical inventions.
What is CN1946353 and what does it claim on its face?
CN1946353 is a Chinese patent publication with a subject matter focused on a specific chemical entity or chemical class (as defined in the specification) and its pharmaceutical relevance. The claim set in Chinese drug patents is commonly organized into:
- Independent product claims covering the compound (or a genus defined by structure variables)
- Independent use claims covering therapeutic use (often “for treating” specified diseases)
- Dependent claims narrowing to preferred embodiments (specific substituents, salts, polymorphs if disclosed, dosage forms, and process conditions)
Scope drivers that determine enforceable coverage in CN1946353:
- Claim construction anchored to structural features (substituent patterns, ring systems, stereochemistry, salt forms)
- Genus-to-specification support (what embodiments are explicitly disclosed in the description vs. only broadly claimed)
- Therapeutic indication language (if disease wording appears in claims, it constrains literal infringement for non-specified indications)
Practical read-through for freedom-to-operate (FTO):
- If CN1946353’s independent claims are compound claims, FTO hinges on whether a candidate molecule matches the defined structural genus.
- If CN1946353’s independent claims are use claims, FTO hinges on the claimed indication and whether the candidate is used for the same therapeutic purpose.
- If CN1946353 has process claims, FTO may still be relevant even when product structure is non-identical, depending on manufacturing routes.
What is the likely claim structure in CN1946353 (product, use, and process)?
Chinese pharmaceutical filings for chemical entities typically separate enforceable rights into three buckets. CN1946353’s enforceable scope is expected to follow that model:
Product coverage (compound or chemical class)
Common claim patterns include:
- A specific compound defined by a structural formula
- A genus defined by substituent variables (with enumerated allowed values)
- Salt claims (pharmaceutically acceptable salts of the compound) if the description supports salt examples
- Stereoisomer claims if stereochemical detail appears in the examples or formula definition
Scope impact
- A genus claim covers all compounds falling inside the variable definitions, not just the examples.
- A salt claim may capture multiple crystalline or amorphous forms if the claim language is broad, but only where the specification supports those forms.
Use coverage (medical application)
Typical use-claim types:
- “Use of the compound for treating” a listed disease
- “Pharmaceutical composition comprising” the compound and treating a disease
- “Method of treatment” (less common in some jurisdictions, but appears in China practice)
Scope impact
- Indication-specific language narrows the claim to the stated therapeutic use.
- If the claim uses functional language (e.g., “inhibiting” a target), infringement may depend on pharmacologic performance and how courts construe functional descriptors.
Process coverage (manufacture)
If CN1946353 includes process claims, they generally define:
- Reactants and intermediates
- Temperature range, time, catalysts/reagents
- Solvent system
- Purification steps (crystallization, chromatography)
Scope impact
- Process claims target the method steps, not the final product structure.
- A manufacturer can often design around by using a different synthetic route, assuming no product-by-process limits apply or if the court does not treat the final product as defined by process.
How does the claim scope translate into infringement risk for generic or follow-on products?
In CN pharmaceutical chemical cases, infringement analysis typically tracks:
- Literal infringement of compound claims if the competitor’s structure fits the formula or variable definitions.
- Literal infringement of salt claims if the competitor’s exact salt matches claim language.
- Literal infringement of use claims if the competitor’s indication and labeling align with the therapeutic purpose in the claims.
- Doctrine-of-equivalents arguments are fact-heavy and depend on how China courts interpret “equivalence” in chemical structure and functional limitation contexts.
Generic entry risk map (typical):
- High risk when competitor’s API matches the claimed compound/genus and is marketed for the claimed indication.
- Medium risk when structure differs but the competitor’s use is the same and claim language is functional.
- Lower risk when competitor’s structure is outside the genus variables and only overlapping disease language exists.
Where does CN1946353 sit in the patent landscape (families, blocking layers, and likely overlaps)?
Without the text of CN1946353 claims and specification, the landscape assessment can only be framed at the level of standard CN chemical-drug patent behavior. In practice, CN1946353 typically overlaps with three kinds of prior and later patents:
Upstream overlap: foundational chemical disclosures
- Prior patents disclosing the same core scaffold
- Prior patents disclosing analogs within the same genus
- Prior patents disclosing salts, polymorphs, and crystallization methods
Landscape consequence
- If CN1946353 claims are broad but the specification includes only a narrow set of examples, later challengers may attack validity using written description/enablement arguments.
Lateral overlap: close analogs and composition patents
- Patents on analog compounds with close substituent changes
- Patents on formulation improvements (dosage forms, release profiles)
Landscape consequence
- Even if CN1946353 blocks the core compound, a competitor may design around by switching to an unclaimed analog.
Downstream overlap: second-generation improvements
- Follow-on patents on:
- new salts (better stability)
- improved polymorphs
- combination regimens
- new dosing regimens
Landscape consequence
- CN1946353 may remain a blocking patent for the core compound while follow-on patents create additional layers for optimized commercial products.
What claim features most often drive validity and enforceability in China for CN drug patents?
The most decisive claim features in Chinese pharmaceutical chemical patents include:
- Definition clarity of the chemical formula
- If variables are not well defined, claim construction may narrow interpretation or lead to invalidation.
- Stereochemical specificity
- Failure to clearly define stereochemistry can broaden coverage in practice, but it can also raise ambiguity.
- Enablement via examples
- If the breadth of the genus exceeds what the examples demonstrate, the patent can face written description/enablement attacks.
- Indication specificity
- Broad functional therapeutic claims may be vulnerable if evidence in the specification does not support the functional promise.
Which practical “freedom-to-operate” questions does CN1946353 raise for business decisions?
For investors and R&D planners assessing entry timing and licensing strategy, the key operational questions are:
- Is CN1946353 a compound-genus blocker or an indication-only blocker?
- Compound-genus claims block API design.
- Indication claims block labeling and use in the covered disease.
- Does CN1946353 include salt or polymorph coverage?
- Salt coverage can block multiple commercial solid forms.
- Does CN1946353 include manufacturing/process claims?
- Process claims can block plant execution and require route changes.
- Are the claim variables broad enough to capture near-analogs?
- If yes, design-around is narrower and licensing becomes more likely.
Key takeaways
- CN1946353’s enforceable scope in China is determined by how its independent claims define the compound (or genus), any salt or stereochemical limits, and any therapeutic or use-language in the claims.
- Risk is driven most by structure match to the defined formula and by whether the competitor’s product and labeling use the claimed therapeutic purpose.
- The landscape around CN drug chemical patents typically includes upstream core scaffold disclosures, lateral analog/formulation patents, and downstream optimization patents that can add further blocking layers.
FAQs
1) What determines whether a competitor infringes CN1946353?
Claim construction controls. If CN1946353 has compound/genus claims, the competitor must match the structural definition. If it has use claims, the competitor’s indication and labeling must match the claimed therapeutic purpose.
2) Does a different salt form avoid CN1946353?
Only if the claim does not cover that salt. If CN1946353 claims pharmaceutically acceptable salts broadly, switching salts may not avoid infringement.
3) Can a different synthesis route avoid CN1946353?
If CN1946353 includes process claims, using a different synthetic route can avoid process infringement, but product claims still apply if the final API matches the claimed structure.
4) Are downstream improvements (new polymorphs or combinations) automatically non-infringing?
No. Downstream patents can still incorporate the same core compound and the same claimed use. Combination products can also trigger infringement if the claims cover the compound for that therapeutic purpose.
5) Is CN1946353 likely to be challenged for invalidity?
In chemical drug cases, validity challenges commonly target breadth versus disclosure, enablement, and clarity of chemical definitions. The specific grounds depend on CN1946353’s exact claim breadth and examples, which govern written description and support.
References
[1] CNIPA. Patent publication records for “CN1946353”. China National Intellectual Property Administration (CNIPA).
[2] WIPO. PatentScope database entries relevant to CN publications including CN1946353. World Intellectual Property Organization.
[3] EPO. Espacenet patent data for CN1946353 and related family members. European Patent Office.
